MEREO BIOPHARMA (MREO)
(Real Time Quote from BATS)
$2.78 USD
-0.03 (-1.07%)
Updated Apr 26, 2024 10:32 AM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for MEREO BIOPHARMA falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 57 | 70 | 130 | 30 | 21 |
Receivables | 0 | 2 | 3 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 4 | 6 | 16 |
Total Current Assets | 64 | 77 | 137 | 38 | 39 |
Net Property & Equipment | 0 | 2 | 3 | 2 | 15 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 30 | 34 | 41 | 57 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 67 | 109 | 174 | 81 | 110 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 4 | 3 | 4 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 19 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 6 | 5 | 5 | 7 |
Income Taxes Payable | 0 | 0 | 2 | 0 | 0 |
Other Current Liabilities | 1 | 21 | 6 | 1 | 1 |
Total Current Liabilities | 9 | 31 | 17 | 11 | 38 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 4 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 20 | 21 | 7 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 13 | 67 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16 | 32 | 53 | 100 | 59 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 2 | 2 | 1 | 0 |
Capital Surplus | 486 | 479 | 519 | 373 | 231 |
Retained Earnings | -420 | -410 | -408 | -398 | -187 |
Other Equity | -17 | 5 | 8 | 5 | 7 |
Treasury Stock | 1 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 51 | 77 | 121 | -19 | 51 |
Total Liabilities & Shareholder's Equity | 67 | 109 | 174 | 81 | 110 |
Total Common Equity | 51 | 77 | 121 | -19 | 51 |
Shares Outstanding | 124.90 | 124.90 | 116.90 | 67.70 | 24.90 |
Book Value Per Share | 0.40 | 0.61 | 1.04 | -0.28 | 2.06 |
Fiscal Year End for MEREO BIOPHARMA falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 57 | -99,999 | -99,946 | -99,999 |
Receivables | NA | 0 | NA | 11 | NA |
Notes Receivable | NA | 0 | NA | NA | NA |
Inventories | NA | 0 | NA | NA | NA |
Other Current Assets | NA | 6 | NA | 4 | NA |
Total Current Assets | NA | 64 | NA | 68 | NA |
Net Property & Equipment | NA | 0 | NA | 2 | NA |
Investments & Advances | NA | 0 | NA | NA | NA |
Other Non-Current Assets | NA | 0 | NA | NA | NA |
Deferred Charges | NA | 0 | NA | NA | NA |
Intangibles | NA | 1 | NA | 31 | NA |
Deposits & Other Assets | NA | 0 | NA | NA | NA |
Total Assets | NA | 67 | NA | 101 | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | NA | NA |
Accounts Payable | NA | 2 | NA | 2 | NA |
Current Portion Long-Term Debt | NA | 0 | NA | 5 | NA |
Current Portion Capital Leases | NA | 0 | NA | NA | NA |
Accrued Expenses | NA | 5 | NA | 6 | NA |
Income Taxes Payable | NA | 0 | NA | NA | NA |
Other Current Liabilities | NA | 1 | NA | 8 | NA |
Total Current Liabilities | NA | 9 | NA | 22 | NA |
Mortgages | NA | 0 | NA | NA | NA |
Deferred Taxes/Income | NA | 0 | NA | NA | NA |
Convertible Debt | NA | 4 | NA | 5 | NA |
Long-Term Debt | NA | 0 | NA | NA | NA |
Non-Current Capital Leases | NA | 0 | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | 1 | NA | |
Minority Interest (Liabilities) | NA | 0 | NA | NA | NA |
Total Liabilities | NA | 16 | NA | 29 | NA |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | NA | NA |
Common Stock (Par) | NA | 3 | NA | 2 | NA |
Capital Surplus | NA | 486 | NA | 491 | NA |
Retained Earnings | NA | -420 | NA | -428 | NA |
Other Equity | NA | -17 | NA | 7 | NA |
Treasury Stock | NA | 1 | NA | NA | NA |
Total Shareholder's Equity | NA | 51 | NA | 72 | NA |
Total Liabilities & Shareholder's Equity | NA | 67 | NA | 101 | NA |
Total Common Equity | 0 | 51 | 0 | 100,071 | 0 |
Shares Outstanding | 124.90 | 124.90 | 124.90 | 124.90 | 124.90 |
Book Value Per Share | 0.00 | 0.40 | 0.00 | 801.21 | 0.00 |